

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number	New Application
Filing Date	
First Named Inventor	Dillon, Michael Patrick <i>et al.</i>
Group Art Unit	unassigned
Examiner Name	
Attorney Docket Number	R0130C-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office 3	Number ⁴	Kind Code ⁵ (if known)				
	B1	GB	1336 228		Merck & Co., Inc. -USA	11-07-1973		
	B2	EP	0 887 436	A2	F. Hoffmann- La Roche AG, CH	12-30-1998		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	NARDI, D., et al., Hypertensive Activity of 2-(2,3,4,6-tetramethylbenzyl) imidazoline and related compounds," (Research on Durene Derivatives), <i>Farmaco., Ed. Sci.</i> (1979) pp. 789-801, vol. 34(9)	
	C2	LIS, R., et al., "Synthesis and Antiarrhythmic Activity of Novel 3-Alkyl-1-[ω-[4- [(alkylsulfonyl)amino]phenyl]-ω-hydroxyalkyl]-1H-imidazolium Salts and Related Compounds," <i>J. Med. Chem.</i> , (1987), pp. 2303-2309, vol. 30.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Doc. #120553v1

Please type a plus sign (+) inside this box →

+

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/421,119

Filing Date

April 22, 2003

First Named Inventor

Dillon, Michael Patrick *et al.*

Group Art Unit

1626

Examiner Name

Stockton, Laura

Attorney Docket Number

R0130C-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	US 2002/0169193	A1	Pouzet, Pascale, <i>et al.</i>	11-14-2002	
	A2	US 6,602,897	B2	Esser, Franz, <i>et al.</i>	08-05-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office 3	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Doc. #122759v1

BEST AVAILABLE COPY